WO1994001095A2 - Medicaments pour le traitement de douleurs viscerales et de migraines - Google Patents
Medicaments pour le traitement de douleurs viscerales et de migraines Download PDFInfo
- Publication number
- WO1994001095A2 WO1994001095A2 PCT/GB1993/001377 GB9301377W WO9401095A2 WO 1994001095 A2 WO1994001095 A2 WO 1994001095A2 GB 9301377 W GB9301377 W GB 9301377W WO 9401095 A2 WO9401095 A2 WO 9401095A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dose
- receptor antagonist
- treatment
- composition according
- active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Definitions
- This invention relates to the use of certain compounds which are 5-HT3 receptor antagonists as visceral analgesics.
- EP-A-279512 (Beecham Group p.l.c.) describes the use of certain 5-HT3 receptor antagonists, including granisetron (KYTRIL) in the treatment of visceral pain.
- KYTRIL granisetron
- Visceral pain is a symptom of irritable bowel syndrome (IBS) and granisetron has been found to desensitise the rectum in IBS patients as shown by double-blind placebo-controlled studies, at doses of 120 ⁇ g/kg and 50 ⁇ g/kg, 120 ⁇ g/kg being most effective. (Prior and Read, 1990; Gut 11 (10) A1174).
- Granisetron has been found to be active in an animal model of rectal sensitivity to distension (see method described hereafter).
- 5-HT3 receptor antagonists which have the same effect as granisetron in this model, include zatosetron (Lilly) and metoclopramide.
- the invention therefore relates to the use of those 5-HT3 receptor antagonists, which are active in the animal model at a dose determined as the dose at which 5-HT3 receptor antagonist activity is observed in standard tests, such as the Bezold-Jarisch model, in the treatment of visceral pain, such as the pain symptoms of IBS, and also migraine.
- Preferred compounds are active at a lower dose than the 5-HT3 receptor antagonist dose.
- Compounds which are approved or under clinical investigation are active at a similar dosage level to that which is used for antiemetic use.
- 5-HT3 receptor antagonists which should be considered for this invention include those specifically and generically disclosed and referenced in EP-A-450757 (Glaxo Group Limited). Rat Model of Colo-rectal Distension
- a 6-7 cm latex balloon was inserted intra-anally into male Wistar rats (250-650g) under halothane anaesthesia; the balloon catheter was taped to the tail. After recovery the animals were allowed unrestricted movement and were dosed with either vehicle (saline) or 5-hydroxytryptophan (5-HTP lOmgkg " ! subcutaneously).
- vehicle saline
- 5-hydroxytryptophan 5-hydroxytryptophan
- 5-HT3 receptor antagonists or saline were dosed subcutaneously after 3 stable responses were achieved and within 45 min of dosing 5-HTP or vehicle.
- the visceromotor threshold values were then recorded for a further 30 min.
- a similar model was described by Ness & Gebhart (1988, Brain Res. 450. 153-169). Maximum percentage changes (within the 30 min post-dose period) in distension pressure were compared with the mean of the pre-dose recordings. Saline control values were then assigned the value of 1.00 and drug induced changes compared directly.
- Intrathecal administration of granisetron also showed good analgesic activity suggesting that a site of action, of those 5-HT3 receptor antagonists that are visceral analgesics, may be in the spinal cord.
- 5-HT3 receptor antagonists that are visceral analgesics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002139440A CA2139440A1 (fr) | 1992-07-03 | 1993-06-30 | Medicaments pour le traitement des douleurs viscerales et de la migraine |
EP93914854A EP0650355A1 (fr) | 1992-07-03 | 1993-06-30 | Medicaments pour le traitement de douleurs viscerales et de migraines |
AU45076/93A AU4507693A (en) | 1992-07-03 | 1993-06-30 | Medicaments for the treatment of visceral pain and migraine |
JP6503078A JPH07508530A (ja) | 1992-07-03 | 1993-06-30 | 内臓の痛みおよび偏頭痛の治療薬 |
KR1019940704887A KR950702112A (ko) | 1992-07-03 | 1994-12-31 | 내장 진통 및 편두통의 치료 약물(Medicaments for the treatment of visceral pain and migraine) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929214184A GB9214184D0 (en) | 1992-07-03 | 1992-07-03 | Pharmaceuticals |
GB9214184.5 | 1992-07-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994001095A2 true WO1994001095A2 (fr) | 1994-01-20 |
WO1994001095A3 WO1994001095A3 (fr) | 1994-04-14 |
Family
ID=10718169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/001377 WO1994001095A2 (fr) | 1992-07-03 | 1993-06-30 | Medicaments pour le traitement de douleurs viscerales et de migraines |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0650355A1 (fr) |
JP (1) | JPH07508530A (fr) |
KR (1) | KR950702112A (fr) |
AU (1) | AU4507693A (fr) |
CA (1) | CA2139440A1 (fr) |
GB (1) | GB9214184D0 (fr) |
WO (1) | WO1994001095A2 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5726187A (en) * | 1992-10-16 | 1998-03-10 | Smithkline Beecham Plc | N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists |
US5852014A (en) * | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
WO1999017755A2 (fr) * | 1997-10-07 | 1999-04-15 | Glaxo Group Limited | Medicaments |
US5998409A (en) * | 1992-03-12 | 1999-12-07 | Smithkline Beecham Plc | Condensed indole derivatives as 5HT4 -receptor antagonists |
WO2000048581A2 (fr) * | 1999-02-18 | 2000-08-24 | Novartis Ag | Utilisation d'antagonistes du recepteur 5-ht¿3? |
WO2001041748A2 (fr) * | 1999-12-10 | 2001-06-14 | Novartis Ag | Combinaisons pharmaceutiques et leur utilisation dans le traitement de troubles gastro-intestinaux |
US7094786B2 (en) | 2003-01-13 | 2006-08-22 | Dynogen Pharmaceuticals, Inc. | Method of treating nausea, vomiting, retching or any combination thereof |
US7470690B2 (en) | 2002-07-10 | 2008-12-30 | Dynogen Pharmaceuticals, Inc. | 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder |
US7608282B2 (en) * | 2003-02-05 | 2009-10-27 | Strakan International Limited | Transdermal granisetron |
US8246981B2 (en) | 2005-05-18 | 2012-08-21 | Abeille Pharamaceuticals, Inc. | Transdermal method and patch for emesis |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19807535A1 (de) * | 1998-02-21 | 1999-08-26 | Asta Medica Ag | Pharmazeutische Kombinationen mit Tramadol |
Citations (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0189002A2 (fr) * | 1984-12-20 | 1986-07-30 | Sandoz Ag | Traitement de maladies gastro-intestinales utilisant des 5-HT3 antagonistes |
EP0254584A2 (fr) * | 1986-07-25 | 1988-01-27 | Beecham Group Plc | Composés azabicycliques, procédé pour leur préparation et leur utilisation pharmaceutique |
GB2192885A (en) * | 1986-07-23 | 1988-01-27 | Glaxo Group Ltd | Heterocyclic compounds |
EP0266899A2 (fr) * | 1986-10-03 | 1988-05-11 | Glaxo Group Limited | Dérivés d'indole |
EP0272876A2 (fr) * | 1986-12-17 | 1988-06-29 | Glaxo Group Limited | Application des dérivés hétérocycliques pour la fabrication de médicaments |
EP0279512A2 (fr) * | 1987-01-19 | 1988-08-24 | Beecham Group Plc | Emploi de certains antagonistes du récépteur 5-HT3 pour le traitement des douleurs viscérales |
EP0287196A1 (fr) * | 1987-02-18 | 1988-10-19 | Beecham Group Plc | Dérivés de l'indole, un procédé pour leur préparation et compositions pharmaceutiques les contenant |
EP0289170A2 (fr) * | 1987-04-25 | 1988-11-02 | Beecham Group Plc | Composés azabicycliques, leur procédé de préparation et compositions pharmaceutiques les contenant |
EP0315316A2 (fr) * | 1987-10-02 | 1989-05-10 | Beecham Group Plc | Dérivés d'imidazole, procédé pour leur préparation, compositions pharmaceutiques les contenant, et leur application pharmaceutique |
EP0315390A2 (fr) * | 1987-11-04 | 1989-05-10 | Beecham Group Plc | Composés nouveaux de 4-oxobenzotriazine et 4-oxoquinazoline |
EP0317088A1 (fr) * | 1987-10-22 | 1989-05-24 | Glaxo Group Limited | Dérivés cétoniques |
WO1989009217A1 (fr) * | 1988-03-23 | 1989-10-05 | Beecham Group Plc | Nouveaux composes |
EP0336759A1 (fr) * | 1988-04-07 | 1989-10-11 | Glaxo Group Limited | Dérivés d'imidazole |
EP0345956A1 (fr) * | 1988-05-20 | 1989-12-13 | Glaxo Group Limited | Cétones tricycliques |
EP0347229A1 (fr) * | 1988-06-16 | 1989-12-20 | Glaxo Group Limited | Dérivés de l'indole |
EP0351385A2 (fr) * | 1988-07-12 | 1990-01-17 | BOEHRINGER INGELHEIM ITALIA S.p.A. | Dérivés d'amidino et de guanidino |
EP0356098A2 (fr) * | 1988-08-15 | 1990-02-28 | Glaxo Group Limited | Dérivés de lactames |
EP0357416A2 (fr) * | 1988-09-01 | 1990-03-07 | Glaxo Group Limited | Utilisation des antagonistes de la sérotonine dans le traitement de l'asservissement aux drogues |
EP0358903A2 (fr) * | 1988-07-29 | 1990-03-21 | Dainippon Pharmaceutical Co., Ltd. | Dérivés d'acide indazole-3-carboxylique |
EP0361317A2 (fr) * | 1988-09-27 | 1990-04-04 | Fujisawa Pharmaceutical Co., Ltd. | Dérivés de pyridoindole et leur procédé de préparation |
EP0364274A1 (fr) * | 1988-10-13 | 1990-04-18 | Glaxo Group Limited | Dérivés d'imidazole |
EP0376624A1 (fr) * | 1988-12-22 | 1990-07-04 | Yamanouchi Pharmaceutical Co. Ltd. | Dérivés de 4,5,6,7-tétrahydrobenzimidazole et leur préparation |
EP0377967A2 (fr) * | 1988-12-13 | 1990-07-18 | Beecham Group Plc | Dérivés du 9-aza-3-(oxa/thia)-bicyclo[3,2,1]nonane, procédé et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant |
EP0381422A1 (fr) * | 1989-02-02 | 1990-08-08 | Yamanouchi Pharmaceutical Co. Ltd. | Dérivés de tétrahydrobenzimidazole |
EP0385722A2 (fr) * | 1989-02-28 | 1990-09-05 | Glaxo Group Limited | Dérivés de tricyclique lactame et les compositions pharmaceutiques qui les contiennent |
EP0387431A1 (fr) * | 1989-03-14 | 1990-09-19 | Beecham Group Plc | Dérivés d'imidazole, procédés de leur préparation et leur application comme produits pharmaceutiques |
WO1991001316A1 (fr) * | 1989-07-21 | 1991-02-07 | Beecham Group Plc | Nouveau derive de 9-azabicyclo[3.3.1] nonane |
EP0417746A2 (fr) * | 1989-09-11 | 1991-03-20 | G.D. Searle & Co. | Amides d'acides aromatiques N-substituées par azabicyclo[3.3.0]octane |
EP0419397A1 (fr) * | 1989-09-08 | 1991-03-27 | Novo Nordisk A/S | Dérivés de l'urée, leur préparation et leur utilisation |
WO1991007402A1 (fr) * | 1989-11-17 | 1991-05-30 | Pfizer Inc. | Amides et esters azabicyliques antagonistes du recepteur de 5-ht¿3? |
WO1991012254A1 (fr) * | 1990-02-16 | 1991-08-22 | Novo Nordisk A/S | Composes d'uree substitues, preparation et utilisation des ces composes |
EP0450757A2 (fr) * | 1990-02-22 | 1991-10-09 | Glaxo Group Limited | Utilisation des antagonistes du 5-hydroxytryptamine pour le traitement des maladies mentales dès l'origine de l'enfance |
EP0451538A2 (fr) * | 1990-03-19 | 1991-10-16 | Fujisawa Pharmaceutical Co., Ltd. | Utilisation des dérivés du pyridoindole dans le traitement des troubles ischémiques |
EP0454121A2 (fr) * | 1990-04-27 | 1991-10-30 | G.D. Searle & Co. | Composés azatétracycliques |
WO1992005174A1 (fr) * | 1990-09-26 | 1992-04-02 | Beecham Group Plc | Derives de 3,9-diazabicyclo (3.3.1) nonan-7-yl, procede et intermediaires de preparation et compositions pharmaceutiques les contenant |
US5126343A (en) * | 1989-09-11 | 1992-06-30 | G. D. Searle & Co. | N-azabicyclo [3.3.0]octane amides of aromatic acids |
WO1992011259A1 (fr) * | 1990-12-19 | 1992-07-09 | Beecham Group Plc | Amides azabicycliques ou esters d'acides benzoïques halogenes |
WO1992012149A1 (fr) * | 1991-01-09 | 1992-07-23 | Smithkline Beecham Plc | Derives azabicydiques et azatricydiques, leurs procedes et intermediaires de preparation et compositions pharmaceutiques les contenant |
US5137893A (en) * | 1991-03-07 | 1992-08-11 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
WO1992014733A1 (fr) * | 1991-02-23 | 1992-09-03 | Smithkline Beecham P.L.C. | Produits pharmaceutiques |
EP0504679A1 (fr) * | 1991-03-07 | 1992-09-23 | G.D. Searle & Co. | Imidazopyridines comme antagonistes 5-HT3 sérotonergiques |
EP0518767A2 (fr) * | 1991-06-11 | 1992-12-16 | Merrell Pharmaceuticals Inc. | Dérivés d'analogues d'amide de quinolizines à pont méthano |
EP0554794A1 (fr) * | 1992-02-04 | 1993-08-11 | Eisai Co., Ltd. | Dérivés d'acides aminobenzoiques |
-
1992
- 1992-07-03 GB GB929214184A patent/GB9214184D0/en active Pending
-
1993
- 1993-06-30 WO PCT/GB1993/001377 patent/WO1994001095A2/fr not_active Application Discontinuation
- 1993-06-30 AU AU45076/93A patent/AU4507693A/en not_active Abandoned
- 1993-06-30 JP JP6503078A patent/JPH07508530A/ja active Pending
- 1993-06-30 CA CA002139440A patent/CA2139440A1/fr not_active Abandoned
- 1993-06-30 EP EP93914854A patent/EP0650355A1/fr not_active Withdrawn
-
1994
- 1994-12-31 KR KR1019940704887A patent/KR950702112A/ko not_active Application Discontinuation
Patent Citations (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0189002A2 (fr) * | 1984-12-20 | 1986-07-30 | Sandoz Ag | Traitement de maladies gastro-intestinales utilisant des 5-HT3 antagonistes |
GB2192885A (en) * | 1986-07-23 | 1988-01-27 | Glaxo Group Ltd | Heterocyclic compounds |
EP0254584A2 (fr) * | 1986-07-25 | 1988-01-27 | Beecham Group Plc | Composés azabicycliques, procédé pour leur préparation et leur utilisation pharmaceutique |
EP0266899A2 (fr) * | 1986-10-03 | 1988-05-11 | Glaxo Group Limited | Dérivés d'indole |
EP0272876A2 (fr) * | 1986-12-17 | 1988-06-29 | Glaxo Group Limited | Application des dérivés hétérocycliques pour la fabrication de médicaments |
EP0279512A2 (fr) * | 1987-01-19 | 1988-08-24 | Beecham Group Plc | Emploi de certains antagonistes du récépteur 5-HT3 pour le traitement des douleurs viscérales |
EP0287196A1 (fr) * | 1987-02-18 | 1988-10-19 | Beecham Group Plc | Dérivés de l'indole, un procédé pour leur préparation et compositions pharmaceutiques les contenant |
EP0289170A2 (fr) * | 1987-04-25 | 1988-11-02 | Beecham Group Plc | Composés azabicycliques, leur procédé de préparation et compositions pharmaceutiques les contenant |
EP0315316A2 (fr) * | 1987-10-02 | 1989-05-10 | Beecham Group Plc | Dérivés d'imidazole, procédé pour leur préparation, compositions pharmaceutiques les contenant, et leur application pharmaceutique |
EP0317088A1 (fr) * | 1987-10-22 | 1989-05-24 | Glaxo Group Limited | Dérivés cétoniques |
EP0315390A2 (fr) * | 1987-11-04 | 1989-05-10 | Beecham Group Plc | Composés nouveaux de 4-oxobenzotriazine et 4-oxoquinazoline |
WO1989009217A1 (fr) * | 1988-03-23 | 1989-10-05 | Beecham Group Plc | Nouveaux composes |
EP0336759A1 (fr) * | 1988-04-07 | 1989-10-11 | Glaxo Group Limited | Dérivés d'imidazole |
EP0345956A1 (fr) * | 1988-05-20 | 1989-12-13 | Glaxo Group Limited | Cétones tricycliques |
EP0347229A1 (fr) * | 1988-06-16 | 1989-12-20 | Glaxo Group Limited | Dérivés de l'indole |
EP0351385A2 (fr) * | 1988-07-12 | 1990-01-17 | BOEHRINGER INGELHEIM ITALIA S.p.A. | Dérivés d'amidino et de guanidino |
EP0358903A2 (fr) * | 1988-07-29 | 1990-03-21 | Dainippon Pharmaceutical Co., Ltd. | Dérivés d'acide indazole-3-carboxylique |
EP0356098A2 (fr) * | 1988-08-15 | 1990-02-28 | Glaxo Group Limited | Dérivés de lactames |
EP0357416A2 (fr) * | 1988-09-01 | 1990-03-07 | Glaxo Group Limited | Utilisation des antagonistes de la sérotonine dans le traitement de l'asservissement aux drogues |
EP0361317A2 (fr) * | 1988-09-27 | 1990-04-04 | Fujisawa Pharmaceutical Co., Ltd. | Dérivés de pyridoindole et leur procédé de préparation |
EP0364274A1 (fr) * | 1988-10-13 | 1990-04-18 | Glaxo Group Limited | Dérivés d'imidazole |
EP0377967A2 (fr) * | 1988-12-13 | 1990-07-18 | Beecham Group Plc | Dérivés du 9-aza-3-(oxa/thia)-bicyclo[3,2,1]nonane, procédé et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant |
EP0376624A1 (fr) * | 1988-12-22 | 1990-07-04 | Yamanouchi Pharmaceutical Co. Ltd. | Dérivés de 4,5,6,7-tétrahydrobenzimidazole et leur préparation |
EP0381422A1 (fr) * | 1989-02-02 | 1990-08-08 | Yamanouchi Pharmaceutical Co. Ltd. | Dérivés de tétrahydrobenzimidazole |
EP0385722A2 (fr) * | 1989-02-28 | 1990-09-05 | Glaxo Group Limited | Dérivés de tricyclique lactame et les compositions pharmaceutiques qui les contiennent |
EP0387431A1 (fr) * | 1989-03-14 | 1990-09-19 | Beecham Group Plc | Dérivés d'imidazole, procédés de leur préparation et leur application comme produits pharmaceutiques |
WO1991001316A1 (fr) * | 1989-07-21 | 1991-02-07 | Beecham Group Plc | Nouveau derive de 9-azabicyclo[3.3.1] nonane |
EP0419397A1 (fr) * | 1989-09-08 | 1991-03-27 | Novo Nordisk A/S | Dérivés de l'urée, leur préparation et leur utilisation |
US5126343A (en) * | 1989-09-11 | 1992-06-30 | G. D. Searle & Co. | N-azabicyclo [3.3.0]octane amides of aromatic acids |
EP0417746A2 (fr) * | 1989-09-11 | 1991-03-20 | G.D. Searle & Co. | Amides d'acides aromatiques N-substituées par azabicyclo[3.3.0]octane |
WO1991007402A1 (fr) * | 1989-11-17 | 1991-05-30 | Pfizer Inc. | Amides et esters azabicyliques antagonistes du recepteur de 5-ht¿3? |
WO1991012254A1 (fr) * | 1990-02-16 | 1991-08-22 | Novo Nordisk A/S | Composes d'uree substitues, preparation et utilisation des ces composes |
EP0450757A2 (fr) * | 1990-02-22 | 1991-10-09 | Glaxo Group Limited | Utilisation des antagonistes du 5-hydroxytryptamine pour le traitement des maladies mentales dès l'origine de l'enfance |
EP0451538A2 (fr) * | 1990-03-19 | 1991-10-16 | Fujisawa Pharmaceutical Co., Ltd. | Utilisation des dérivés du pyridoindole dans le traitement des troubles ischémiques |
EP0454121A2 (fr) * | 1990-04-27 | 1991-10-30 | G.D. Searle & Co. | Composés azatétracycliques |
WO1992005174A1 (fr) * | 1990-09-26 | 1992-04-02 | Beecham Group Plc | Derives de 3,9-diazabicyclo (3.3.1) nonan-7-yl, procede et intermediaires de preparation et compositions pharmaceutiques les contenant |
WO1992011259A1 (fr) * | 1990-12-19 | 1992-07-09 | Beecham Group Plc | Amides azabicycliques ou esters d'acides benzoïques halogenes |
WO1992012149A1 (fr) * | 1991-01-09 | 1992-07-23 | Smithkline Beecham Plc | Derives azabicydiques et azatricydiques, leurs procedes et intermediaires de preparation et compositions pharmaceutiques les contenant |
WO1992014733A1 (fr) * | 1991-02-23 | 1992-09-03 | Smithkline Beecham P.L.C. | Produits pharmaceutiques |
US5137893A (en) * | 1991-03-07 | 1992-08-11 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
EP0504679A1 (fr) * | 1991-03-07 | 1992-09-23 | G.D. Searle & Co. | Imidazopyridines comme antagonistes 5-HT3 sérotonergiques |
EP0518767A2 (fr) * | 1991-06-11 | 1992-12-16 | Merrell Pharmaceuticals Inc. | Dérivés d'analogues d'amide de quinolizines à pont méthano |
EP0554794A1 (fr) * | 1992-02-04 | 1993-08-11 | Eisai Co., Ltd. | Dérivés d'acides aminobenzoiques |
Non-Patent Citations (3)
Title |
---|
ALIMENT.PHARMACOL.THER., vol.6, no.3, June 1992 pages 273 - 289 N.J.TALLEY 'REVIEW ARTICLE: 5-HYDROXYTRYPTAMINE AGONISTA AND ANTAGONISTS IN THE MODULATION OF GASTROINTESTINAL MOTILITY AND SENSATION: CLIMICAL IMPLICATIONS' * |
GUT, vol.31, no.10, 1990 page A1174 A. PRIOR ET AL. 'REDUCTION OF RECTAL SENSITIVITY AND POST-PRANDIAL MOTILITY BY GRANISETRON, A 5-HT3 RECEPTOR ANTAGONIST, IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS)' cited in the application * |
R.BERKOW, ED. 'THE MERCK MANUAL OF DIAGNOSIS AND THERAPY, 15TH EDITION' , MERCK & CO. , RAHWAY, N.J. see page 808 - page 810 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5852014A (en) * | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
US5998409A (en) * | 1992-03-12 | 1999-12-07 | Smithkline Beecham Plc | Condensed indole derivatives as 5HT4 -receptor antagonists |
US5726187A (en) * | 1992-10-16 | 1998-03-10 | Smithkline Beecham Plc | N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists |
US6284770B1 (en) | 1997-10-07 | 2001-09-04 | Glaxo Wellcome Inc. | Medicaments for the treatment of non-constipated female irritable bowel syndrome |
WO1999017755A2 (fr) * | 1997-10-07 | 1999-04-15 | Glaxo Group Limited | Medicaments |
WO1999017755A3 (fr) * | 1997-10-07 | 1999-09-23 | Glaxo Group Ltd | Medicaments |
US6593336B2 (en) | 1997-10-07 | 2003-07-15 | Smithkline Beecham Corporation | Methods for treating irritable bowel syndrome |
US6429209B2 (en) | 1997-10-07 | 2002-08-06 | Smithkline Beecham Corporation | Methods for treating irritable bowel syndrome |
WO2000048581A3 (fr) * | 1999-02-18 | 2001-01-11 | Novartis Ag | Utilisation d'antagonistes du recepteur 5-ht¿3? |
WO2000048581A2 (fr) * | 1999-02-18 | 2000-08-24 | Novartis Ag | Utilisation d'antagonistes du recepteur 5-ht¿3? |
US6462065B2 (en) | 1999-02-18 | 2002-10-08 | Novartis Ag | Use of 5-HT3 receptor antagonists for treating musculoeskeletal diseases |
US7393857B2 (en) | 1999-02-18 | 2008-07-01 | Novasearch Ag | Use of 5-HT3 receptor antagonists for treating musculoskeletal diseases |
CN1310644C (zh) * | 1999-12-10 | 2007-04-18 | 诺瓦提斯公司 | 药物组合产品及其在治疗胃肠疾病中的应用 |
EP1488788A1 (fr) * | 1999-12-10 | 2004-12-22 | Novartis AG | Combinaisons pharmaceutiques et leur utilisation pour le traitement de troubles gastro-intestinaux |
WO2001041748A2 (fr) * | 1999-12-10 | 2001-06-14 | Novartis Ag | Combinaisons pharmaceutiques et leur utilisation dans le traitement de troubles gastro-intestinaux |
WO2001041748A3 (fr) * | 1999-12-10 | 2002-12-19 | Novartis Ag | Combinaisons pharmaceutiques et leur utilisation dans le traitement de troubles gastro-intestinaux |
SG152025A1 (en) * | 1999-12-10 | 2009-05-29 | Novartis Ag | Pharmaceutical combinations and their use in treating gastrointestinal disorders |
CZ300690B6 (cs) * | 1999-12-10 | 2009-07-15 | Novartis Ag | Farmaceutická kombinace obsahující tegaserod a omeprazol pro lécení refluxní nemoci jícnu |
US7470690B2 (en) | 2002-07-10 | 2008-12-30 | Dynogen Pharmaceuticals, Inc. | 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder |
US7094786B2 (en) | 2003-01-13 | 2006-08-22 | Dynogen Pharmaceuticals, Inc. | Method of treating nausea, vomiting, retching or any combination thereof |
US7608282B2 (en) * | 2003-02-05 | 2009-10-27 | Strakan International Limited | Transdermal granisetron |
US20100008974A1 (en) * | 2003-02-05 | 2010-01-14 | Strakan International Limited | Transdermal granisetron |
US20120258164A1 (en) * | 2003-02-05 | 2012-10-11 | Strakan International Limited | Transdermal granisetron |
US8246981B2 (en) | 2005-05-18 | 2012-08-21 | Abeille Pharamaceuticals, Inc. | Transdermal method and patch for emesis |
Also Published As
Publication number | Publication date |
---|---|
GB9214184D0 (en) | 1992-08-12 |
EP0650355A1 (fr) | 1995-05-03 |
KR950702112A (ko) | 1995-06-19 |
WO1994001095A3 (fr) | 1994-04-14 |
AU4507693A (en) | 1994-01-31 |
JPH07508530A (ja) | 1995-09-21 |
CA2139440A1 (fr) | 1994-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220062276A1 (en) | Pharmaceutical compositions | |
KR100726699B1 (ko) | 부프레노르핀을 함유하는 진통 조성물 | |
JPH04501425A (ja) | ロラタジン、イブプロフェンおよびプソイドエフェドリンを含む薬剤組成物 | |
PT2124556E (pt) | Composições farmacêuticas | |
US5432176A (en) | Method of retarding the progression of chronic renal failure | |
KR20020016831A (ko) | 비내용 모르핀을 함유하는 의약 조성물 및 그 제조방법 | |
EP0650355A1 (fr) | Medicaments pour le traitement de douleurs viscerales et de migraines | |
US20050011468A1 (en) | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines | |
US20040259898A1 (en) | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines | |
WO2020030991A1 (fr) | Forme posologique à insérer dans la bouche | |
EP0514023B1 (fr) | Utilisation de ligands du récepteur glycine/NMDA pour la fabrication d'un médicament pour le traitement de la dépendence aux drogues et du symptone d'abstinence | |
JP2004043479A (ja) | 経鼻吸収用組成物 | |
JPS61189222A (ja) | 中枢鎮痛剤及びアデニンを活性成分として含有する組合せ薬剤 | |
Tekol et al. | Ephedrine diminishes some side effects of morphine | |
Ghodse et al. | Opioid analgesics and narcotic antagonists | |
GVAX | FDA Drug Approvals | |
JP2013537232A (ja) | 鎮痛をもたらすために、オピオイドの静脈内投与から、投薬アルゴリズムを用いたモルヒネおよびオキシコドンの経口共投与へと、患者の処置レジメンを変換する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: AT,BB,BG,BR,CZ,DE,DK,FI,GB,HU,KP,KZ,LK,LU,MG,MN,MW,NL,NO,NZ,PL,PT,RO,RU,SD,SE,SK,UA, OAPI PATENT(BF,BJ,CF,CG,CI,CM,GA,GN,ML,MR,NE,SN,TD,TG) |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993914854 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2139440 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1995 360669 Country of ref document: US Date of ref document: 19950309 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1993914854 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993914854 Country of ref document: EP |